Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 randomized, double-blind, placebo-controlled trial of BMN 111 (vosoritide) in infants and young children with achondroplasia
2016-003826-18Phase 2Unknown
- Sponsor
- BioMarin Pharmaceutical Inc.
- Start
- May 2018
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in achondroplasia (ACH) comparing Vosoritide with Placebo (2 arms). Primary endpoints: Safety and tolerability of BMN 111 (vosoritide) and Change from baseline in annualized growth velocity (AGV). Status: unknown.
02
Drugs
vosoritide
03
Conditions
achondroplasia (ACH)
Beyond the preview
Go deeper on 2016-003826-18.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-003826-18.